Earnings ·
Werewolf Therapeutics reported second quarter 2026 financial results on July 31, 2026, driven by a $21.0 million asset…
HOWLWerewolf Therapeutics, Inc.
Werewolf Therapeutics reported second quarter 2026 financial results on July 31, 2026, driven by a $21.0 million asset sale of its JZP898 program to Jazz Pharmaceuticals. The transaction enabled the company to repay all amounts owed under its loan and security agreement with K2 HealthVentures LLC. Consequently, the company reported net income of $3.7 million compared to a net loss of $18.0 million in the prior year period. Cash and cash equivalents decreased to $22.0 million from $46.5 million at the end of the first quarter, with management projecting operations will be funded into the second quarter of 2027. The company is currently exploring strategic alternatives with financial advisor Piper Sandler & Co. Werewolf Therapeutics operates in the biopharmaceutical industry, developing conditionally activated therapeutics to stimulate the immune system for cancer treatment.